Amgen (NASDAQ:AMGN) Posts Earnings Results, Beats Expectations By $0.27 EPS

Amgen (NASDAQ:AMGN - Get Free Report) posted its quarterly earnings data on Tuesday. The medical research company reported $5.31 earnings per share (EPS) for the quarter, beating the consensus estimate of $5.04 by $0.27, Zacks reports. Amgen had a return on equity of 168.35% and a net margin of 13.00%.

Amgen Trading Up 0.1 %

AMGN traded up $0.15 during midday trading on Tuesday, reaching $289.02. 3,243,732 shares of the company's stock traded hands, compared to its average volume of 3,136,518. The stock has a market capitalization of $155.36 billion, a price-to-earnings ratio of 37.01, a P/E/G ratio of 2.87 and a beta of 0.56. Amgen has a 52 week low of $253.30 and a 52 week high of $346.85. The firm has a fifty day moving average of $270.95 and a two-hundred day moving average of $303.82. The company has a debt-to-equity ratio of 7.55, a current ratio of 1.32 and a quick ratio of 0.96.

Amgen Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, March 7th. Investors of record on Friday, February 14th will be issued a dividend of $2.38 per share. This represents a $9.52 dividend on an annualized basis and a yield of 3.29%. The ex-dividend date of this dividend is Friday, February 14th. This is an increase from Amgen's previous quarterly dividend of $2.25. Amgen's payout ratio is currently 115.24%.

Wall Street Analyst Weigh In

A number of analysts have recently issued reports on the company. Piper Sandler Companies reiterated an "overweight" rating and set a $310.00 price target on shares of Amgen in a research report on Thursday, January 2nd. StockNews.com lowered shares of Amgen from a "strong-buy" rating to a "buy" rating in a research report on Wednesday, December 18th. Citigroup cut their price target on shares of Amgen from $310.00 to $295.00 and set a "neutral" rating for the company in a research note on Tuesday, January 28th. Royal Bank of Canada restated an "outperform" rating and set a $324.00 price objective on shares of Amgen in a research report on Friday, January 24th. Finally, Leerink Partners cut their target price on shares of Amgen from $349.00 to $302.00 in a research report on Wednesday, November 27th. Two research analysts have rated the stock with a sell rating, twelve have assigned a hold rating, thirteen have given a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of "Hold" and an average price target of $314.00.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.